GORDONSVILLE, Va., June 24 /PRNewswire/ -- PBM Products, LLC, a leading infant formula company that supplies store-brand infant formulas to Walmart, Sam's Club, Target, Kroger, CVS, Walgreens, and other retailers, has partnered with the University of Virginia (U.Va.) to conduct clinical studies on infant nutrition. U.Va. has been collaborating with PBM during the past few years on studies regarding PBM's milk, soy, and specialty infant formulas that compete with expensive national brands, including Enfamil(R) LIPIL(R) and Similac(R) Advance(R) formulas.
"We know breastfeeding is best for babies," said V.P. Cynthia M. Barber, Ph.D., who directs regulatory, medical, and clinical affairs at PBM. "If parents choose to supplement breast milk with formula, our store-brand formulas are nutritionally equivalent to Enfamil(R) LIPIL(R) and Similac(R) Advance(R) formulas and have science and clinical support behind them just like the brand-name formulas do. We feel our clinical work with University of Virginia is strengthening the public perception of store-brand infant formulas, which are as nutritionally complete as the national brand formulas and comply with the same FDA guidelines."
According to James L. Sutphen, M.D., Ph.D., U.Va. Department of Pediatrics and lead researcher on studies involving PBM formulas, it is very common for formula-fed infants to be switched from one formula to another during the first year of life.
"It's important to remember that all infant formulas manufactured and sold in the United States are strictly regulated by the Food and Drug Administration and must be backed by comprehensive growth and development studies," said Dr. Sutphen. "Our work proves there is no physiological reason why you can't switch from one brand of infant formula to another that shares the same protein source, which means store brands are just as nutritionally sound as national-brand formulaPage: 1 2 Related medicine technology :1
. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants2
. Infant Blood May Provide Insights into Diseases Present at Birth3
. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children4
. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease5
. Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill6
. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers7
. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism8
. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists9
. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants10
. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)11
. Pregnant Women Need Omega-3 to Boost Infant Development